Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic
The front-runner coronavirus vaccine appears to protect people from symptomatic disease.
Some experts want to hold out for a more optimal vaccine. Others believe accepting the best possible vaccine sooner than later is ideal.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The treatment reduced coronavirus levels and sped up recovery in a clinical trial.
The trial will test the drug acalabrutinib in those with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.
The pandemic raises new concerns, but it may also lead to long-lasting improvements.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Nearly one in four cancer patients have delayed care, including nonurgent surgery.
The FDA offers researchers new guidance to help keep trials on track.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.